

Edgar Lerma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2862630/publications.pdf>

Version: 2024-02-01

80
papers

4,436
citations

293460

24
h-index

120465

65
g-index

91
all docs

91
docs citations

91
times ranked

6359
citing authors

#	ARTICLE	IF	CITATIONS
1	Lessons learnt and future directions in managing dialysis access during the COVID 19 pandemic: Patient and provider experience in the United States. <i>Journal of Vascular Access</i> , 2023, 24, 213-221.	0.5	3
2	Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. <i>Postgraduate Medicine</i> , 2023, 135, 224-233.	0.9	13
3	Blood Pressure Management in the Patient with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 308-310.	2.2	0
4	Diagnosis 101: diabetic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1797-1799.	1.4	1
5	Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 515-529.	1.3	18
6	PICC line management among patients with chronic kidney disease. <i>Journal of Vascular Access</i> , 2021, , 112972982110258.	0.5	5
7	Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD. <i>Kidney International Reports</i> , 2021, 6, 2292-2304.	0.4	96
8	Optimizing Renin-Angiotensin System Inhibitor Use in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, , CJN.12950921.	2.2	0
9	Kidney transplantation for the primary care provider. <i>Disease-a-Month</i> , 2020, 66, 100869.	0.4	3
10	The Clinical Relevance and Management of High-Flow Arteriovenous Access. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 214-218.	0.6	0
11	A Picture Is Worth a Thousand Views: A Triple Crossover Trial of Visual Abstracts to Examine Their Impact on Research Dissemination. <i>Journal of Medical Internet Research</i> , 2020, 22, e22327.	2.1	52
12	Renal complications during pregnancy: In the hypertension spectrum. <i>Disease-a-Month</i> , 2019, 65, 25-44.	0.4	6
13	Class effects of SGLT2 inhibitors on cardiorenal outcomes. <i>Cardiovascular Diabetology</i> , 2019, 18, 99.	2.7	111
14	Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 798-809.	2.2	124
15	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1027-1036.	2.6	60
16	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
17	Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 760-773.	0.4	115
18	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e840-e878.	1.6	619

#	ARTICLE	IF	CITATIONS
19	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 37-47.	2.6	235
20	Abdominal compartment syndrome. <i>Disease-a-Month</i> , 2019, 65, 5-19.	0.4	36
21	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2018, 93, 1281-1292.	2.6	69
22	Clinical hypertension: Blood pressure variability. <i>Disease-a-Month</i> , 2018, 64, 5-13.	0.4	6
23	Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists. <i>BMC Nephrology</i> , 2018, 19, 147.	0.8	5
24	Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 51-63.	0.5	22
25	Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 41-49.	0.5	50
26	The Evolution of the Journal Club: From Osler to Twitter. <i>American Journal of Kidney Diseases</i> , 2017, 69, 827-836.	2.1	126
27	Nephroendocrinology: When endocrinology meets nephrology. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 1-3.	2.6	7
28	Effects of staged versus ad hoc percutaneous coronary interventions on renal function—Is there a benefit to staging?. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 344-348.	0.3	13
29	Cardio-Renal Syndrome: A double edged sword. <i>Disease-a-Month</i> , 2017, 63, 92-100.	0.4	8
30	Hepatorenal syndrome. <i>Disease-a-Month</i> , 2016, 62, 364-375.	0.4	12
31	Portal hypertension: Etiology, evaluation, and management. <i>Disease-a-Month</i> , 2016, 62, 411-426.	0.4	15
32	Quantifying the Twitter Influence of Third Party Commercial Entities versus Healthcare Providers in Thirteen Medical Conferences from 2011 to 2013. <i>PLoS ONE</i> , 2016, 11, e0162376.	1.1	17
33	Urinary tract infections. <i>Disease-a-Month</i> , 2015, 61, 45-59.	0.4	40
34	NephMadness 2015: Nephrology as a Cornerstone of Medicine. <i>American Journal of Kidney Diseases</i> , 2015, 65, 375-377.	2.1	20
35	Parameters Used to Discontinue Dialysis in Acute Kidney Injury Recovery: A Survey of United States Nephrologists. <i>Nephron</i> , 2015, 130, 41-47.	0.9	9
36	Mineral metabolism in chronic kidney disease. <i>Disease-a-Month</i> , 2015, 61, 425-433.	0.4	5

#	ARTICLE	IF	CITATIONS
37	Diabetes and chronic kidney disease. Disease-a-Month, 2015, 61, 378-386.	0.4	16
38	Hypertension and chronic kidney disease. Disease-a-Month, 2015, 61, 387-395.	0.4	37
39	Nephrolithiasis for the primary care physician. Disease-a-Month, 2015, 61, 434-441.	0.4	1
40	Chronic kidney disease. Disease-a-Month, 2015, 61, 374-377.	0.4	12
41	Cardiovascular disease and chronic kidney disease. Disease-a-Month, 2015, 61, 403-413.	0.4	44
42	Anemia of chronic kidney disease. Disease-a-Month, 2015, 61, 421-424.	0.4	13
43	Dyslipidemia in chronic kidney disease. Disease-a-Month, 2015, 61, 396-402.	0.4	4
44	Autosomal dominant polycystic kidney disease. Disease-a-Month, 2015, 61, 442-447.	0.4	4
45	Improving Care Coordination Between Nephrology and Primary Care: A Quality Improvement Initiative Using the Renal Physicians Association Toolkit. American Journal of Kidney Diseases, 2015, 65, 67-79.	2.1	45
46	Twitter-Based Journal Clubs: Additional Facts and Clarifications. Journal of Medical Internet Research, 2015, 17, e216.	2.1	12
47	Renal LECT2 amyloidosis: a newly described disorder gaining greater recognition. Clinical Nephrology, 2015, 84 (2015), 236-240.	0.4	7
48	Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia. JAMA - Journal of the American Medical Association, 2014, 312, 2223.	3.8	319
49	Lipid, blood pressure and kidney update 2013. International Urology and Nephrology, 2014, 46, 947-961.	0.6	60
50	Multiple myeloma. Disease-a-Month, 2014, 60, 483-488.	0.4	15
51	Sickle cell nephropathy. Disease-a-Month, 2014, 60, 494-499.	0.4	9
52	Thrombotic thrombocytopenic purpura. Disease-a-Month, 2014, 60, 500-504.	0.4	12
53	Renal amyloidosis. Disease-a-Month, 2014, 60, 489-493.	0.4	6
54	HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. American Journal of Cardiovascular Drugs, 2013, 13, 385-398.	1.0	4

#	ARTICLE	IF	CITATIONS
55	Preface. Clinics in Geriatric Medicine, 2013, 29, ix-x.	1.0	0
56	Gastrointestinal and renal excretion of potassium in African-American and White Americans. Journal of Hypertension, 2012, 30, 2373-2377.	0.3	5
57	Statin treatment in patients with elevated liver enzymes: Pitch to proceed. Journal of Clinical Lipidology, 2012, 6, 310-311.	0.6	2
58	Assessment and management of vascular disease risk in patients with chronic kidney disease. Journal of Clinical Lipidology, 2011, 5, 251-260.	0.6	0
59	Are restless legs syndrome, pruritus or hiccoughs surrogates for inadequate dialysis?. Seminars in Dialysis, 2011, 24, 406-407.	0.7	3
60	Clinical Presentation of Nephrolithiasis. Clinical Reviews in Bone and Mineral Metabolism, 2011, 9, 181-186.	1.3	0
61	Hydrochlorothiazide Versus Calcium Channel Blockers: What is the Best Add-on to a Renin-Angiotensin System Blocker for Treating Hypertension in Patients with Renal Disease?. Current Hypertension Reports, 2011, 13, 386-395.	1.5	1
62	Three strikes and statins out: A case against use of statins in dialysis patients for primary prevention. Dialysis and Transplantation, 2011, 40, 148-151.	0.2	0
63	ASTx for preventing progression of chronic kidney disease: What can we conclude from the available evidence?. Dialysis and Transplantation, 2011, 40, 194-195.	0.2	1
64	Tissue plasminogen activator infusion as a treatment for hemodialysis catheter dysfunction. Dialysis and Transplantation, 2010, 39, 97-99.	0.2	1
65	Prevalence of Atrial Fibrillation and Its Predictors in Nondialysis Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 173-181.	2.2	135
66	Foreword. Kidney International, 2009, 76, S1-S2.	2.6	1,242
67	Anatomic and Physiologic Changes of the Aging Kidney. Clinics in Geriatric Medicine, 2009, 25, 325-329.	1.0	17
68	Preface. Clinics in Geriatric Medicine, 2009, 25, xi-xiii.	1.0	0
69	Approach to the Patient with Renal Disease. Primary Care - Clinics in Office Practice, 2008, 35, 183-194.	0.7	9
70	Preface. Primary Care - Clinics in Office Practice, 2008, 35, ix-xi.	0.7	0
71	Preface. Primary Care - Clinics in Office Practice, 2008, 35, xi-xiii.	0.7	0
72	Treatment Options for End Stage Renal Disease. Primary Care - Clinics in Office Practice, 2008, 35, 407-432.	0.7	12

#	ARTICLE	IF	CITATIONS
73	Definition and classification of renal osteodystrophy. Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 3-9.	1.3	0
74	Diagnosis of renal osteodystrophy. Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 21-26.	1.3	1
75	Treatment of renal osteodystrophy. Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 27-38.	1.3	2
76	Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy. Evidence-Based Medicine, 2005, 10, 77-77.	0.6	0
77	Racial differences in potassium disposal. Kidney International, 2004, 66, 1076-1081.	2.6	26
78	Clinical Presentation. Clinical Reviews in Bone and Mineral Metabolism, 2004, 2, 209-216.	1.3	0
79	Pasteurella multocida Peritonitis Another Risk of Animal- Assisted Therapy. Infection Control and Hospital Epidemiology, 2004, 25, 5-6.	1.0	20
80	Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. American Journal of Kidney Diseases, 2001, 38, S51-S56.	2.1	85